1	Iron status in a representative sample of US pregnant women is not associated with pre-
2	pregnancy BMI: results from the NHANES (1999-2010) study
3	
4	
5	
6	Mihaela A. Ciulei <sup>1</sup> , Kelly Gallagher <sup>2</sup> , Djibril Ba <sup>3</sup> , Celeste Beck <sup>1</sup> , Ruth A. Pobee <sup>4</sup> , Alison D.
7	Gernand <sup>1</sup> , Rachel E. Walker <sup>1*</sup>
8	
9	
10	<sup>1</sup> Department of Nutritional Sciences, The Pennsylvania State University, University Park,
11	Pennsylvania, United States of America
12	<sup>2</sup> Ross and Carol Nese College of Nursing, The Pennsylvania State University, University Park,
13	Pennsylvania, United States of America
14	<sup>3</sup> Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania,
15	United States of America
16	<sup>4</sup> Department of Emergency Medicine, University of Illinois at Chicago, Chicago, Illinois, United
17	States of America
18	
19	* Corresponding author:
20	E-mail: rew5009@psu.edu (REW)
21	

# 22 Abstract

23	Iron deficiency in pregnancy is related to many poor health outcomes, including anemia and low
24	birth weight. A small number of previous studies have identified maternal body mass index
25	(BMI) as potential risk factors for poor iron status. Our objective was to examine the association
26	between pre-pregnancy BMI and iron status in a nationally representative sample of US adult
27	women. We used data from the National Health and Nutrition Examination Survey (NHANES;
28	1999-2010) for pregnant women ages 18-49 years (n=1156). BMI (kg/m <sup>2</sup> ) was calculated using
29	pre-pregnancy weight (self-reported) and height (measured at examination). Iron deficiency (ID)
30	was defined as total body iron (calculated from serum ferritin and transferrin receptor using
31	Cook's equation) $< 0$ mg/kg and anemia as hemoglobin $< 11$ g/dL. Associations were examined
32	using weighted Poisson regression models, adjusted for confounders (age, race/ethnicity,
33	education, family income, and trimester). Approximately 14% of pregnant women had ID and
34	8% had anemia in this sample. There were no differences in the prevalence of ID or anemia in
35	women with pre-pregnancy overweight and obesity (ID: overweight, adjusted prevalence ratio
36	(PR)=1.28, 95%CI: 0.89-1.83; obesity, PR=0.75, 95%CI: 0.39-1.45; anemia: overweight,
37	PR=1.08, 95%CI: 0.53-2.19; obesity, PR=0.99, 95%CI: 0.49-2.01) compared to women with a
38	normal BMI. Findings from these US nationally representative data indicate that iron status in
39	pregnancy does not differ by pre-pregnancy BMI. Since iron deficiency during pregnancy
40	remains a significant public health concern, NHANES should consider measuring current iron
41	status in upcoming cycles.

42

43

# 44 Introduction

During pregnancy, iron deficiency (ID) increases the risk of anemia, low birth weight, and infant mortality, while pre-pregnancy obesity increases the risk of Cesarean section, gestational diabetes, and failure to initiate breastfeeding <sup>1–4</sup>, among other outcomes. Both ID and obesity are common in women of reproductive age in the US, especially in populations of minority race and ethnicity <sup>5,6</sup>.

The prevalence of ID increases from about 10% in non-pregnant women of reproductive age 50 to about 16-25% during pregnancy due to blood volume expansion and the increased iron needs 51 to meet fetal and placental demand <sup>7-10</sup>, making it a significant public health concern. The 52 severity of ID increases with higher parity <sup>7,8,11</sup> and across gestation <sup>12,13</sup>. Therefore, pregnancy 53 is a critical period for managing iron status in women of reproductive age. Based on data from 54 the National Health and Nutrition Examination Survey (NHANES) in the US, 18% of pregnant 55 women suffer from ID defined by total body iron <sup>9</sup>. However, these data are over 10 years old 56 since NHANES has not collected biomarkers of functional and circulating iron status combined 57 with gestational age data since 2010. 58

Similarly, obesity is growing in prevalence in the US population in general, including in 59 women of reproductive age. Based on a recent analysis of national data, the prevalence of 60 obesity in women of reproductive age was 29% in 2019 <sup>6</sup>. Some prior studies have suggested that 61 women with obesity are especially vulnerable to the development of ID due to alterations in 62 metabolism and inflammatory signaling <sup>14,15</sup>. A prior review article indicated that pre-pregnancy 63 obesity and overweight pose a risk for ID and ID with anemia (IDA) during pregnancy <sup>16</sup>. 64 However, obesity is highly confounded by a number of demographic factors at a population 65 level, making it imperative to conduct nation-wide investigations that can adjust for 66

67	socioeconomic variation. Given the high prevalence of pre-pregnancy obesity in the US <sup>6</sup> and the
68	importance of iron to promote a healthy pregnancy, a better understanding of the relationship
69	between these factors on a national level could help identify women at higher risk of ID.
70	Although there are previous studies in the US showing an association between obesity and
71	iron status <sup>17,18</sup> , to our knowledge, there are no studies examining iron status and body mass
72	index (BMI) in a US nationally representative sample of pregnant women. Previous studies were
73	performed with a small sample size <sup>17</sup> , in other nations <sup>19–22</sup> , or in adolescents alone <sup>18</sup> .
74	In this study, our objective was to examine iron status by pre-pregnancy BMI category in a
75	nationally representative sample of pregnant women in the US. Based on previous studies, we
76	hypothesized first, that women with pre-pregnancy overweight or obesity would have higher
77	rates of ID, anemia, and IDA during pregnancy compared to women with normal weight.

# 78 Methods

### 79 Study population

80 We conducted a cross-sectional analysis of maternal pre-pregnancy BMI and iron status using data collected in the NHANES study (https://www.cdc.gov/nchs/nhanes/index.htm). We 81 selected the 1999-2010 cycles because they contain data on measured iron status biomarkers in 82 83 addition to pregnancy status, gestational age, and self-reported pre-pregnancy weight. Additionally, these years oversampled pregnant women. In the 12 years (1999-2010; 6 cycles) 84 85 that we selected, there were 62,160 participants, of which 19,569 were between the ages of 18-49 86 years. Next, we restricted the dataset to include only pregnant women (n=1,414) with positive survey sampling weights (n missing=76), which resulted in a sample size of 1,338. We further 87 restricted the dataset to include complete observations for measured height (n missing=6), self-88 89 reported pre-pregnancy weight (n missing=23), and iron and inflammation biomarkers

- 90 (n\_missing=153). Therefore, the final analytic sample consisted of 1,156 participants. The
- 91 original NHANES protocol was approved by the National Center for Health Statistics' Research
- 92 Ethics Review Board <sup>23</sup>, and we used only data publicly available for download.

### 93 Iron and acute inflammation biomarkers

- 94 To characterize iron and inflammation status, NHANES collected maternal venous blood.
- 95 Hemoglobin (Hb) was measured in whole blood, and ferritin, transferrin receptor (TfR), and the
- 96 inflammatory biomarker, C-reactive protein (CRP) were measured in serum by NHANES study
- 97 personnel. Serum and blood samples were collected at a single visit during the mobile
- 98 examination phase of NHANES. A complete description of the protocol used in the collection of
- 99 the iron and inflammatory biomarkers can be found online
- 100 (https://wwwn.cdc.gov/nchs/nhanes/default.aspx).

101 Serum ferritin <sup>24,25</sup> and TfR <sup>26,27</sup> were analyzed using the immunoturbidimetric assay method

- via Roche kits on a Hitachi 912 clinical analyzer for 1999-2008 samples, and on an Elecsys 170
- 103 for ferritin, <sup>28</sup> and Hitachi Mod P for TfR <sup>29</sup> for the 2009-2010 samples. Due to the use of
- 104 different technologies for assessment and following best-practice, we standardized ferritin

105 concentrations using the formula,  $10^{(0.989 * \log_{10}(\text{Hitatchi }912) + 0.049)}$ 

- 106 (https://wwwn.cdc.gov/Nchs/Nhanes/2009-2010/TFR\_F.htm). We calculated total body iron as
- 107  $[\log 10(TfR_{Cook} * 1000/adjusted Ferritin) 2.8229]$  where  $TfR_{Cook} = 1.5 * unadjusted TfR_{Roche} + 0.35$
- to match Cook's standard values  $^{30}$ . We used the total body iron cutoff < 0 mg/kg to classify ID
- <sup>30</sup>. We also defined ID as ferritin < 12  $\mu$ g/L <sup>31</sup> and TfR > 4.4 mg/L <sup>32</sup>. NHANES measured Hb as
- 110 part of the complete blood count analysis using a quantitative cell counter (<sup>33,34</sup> Beckman
- 111 Coulter, Brea, CA). We defined anemia as Hb < 11 g/dL, per Centers for Disease Control and
- 112 Prevention guidelines <sup>31</sup>. The American College of Obstetricians and Gynecologists suggests

113	using a different cutoff (Hb < 10.5 g/dL) for anemia during $2^{nd}$ trimester <sup>35</sup> . However, we chose
114	to use a single cutoff due to the difficulty of classifying a large number of participants with
115	'unknown' or missing trimester data (n=183). Instead, we have included trimester as a covariate
116	in all adjusted models. CRP was assessed with latex-enhanced nephelometry by NHANES 36-38
117	(Dade Behring Inc, Deerfield, IL). We defined inflammation as $CRP > 5 \text{ mg/L}^{39}$ . Ferritin is an
118	acute phase protein and therefore can change in response to inflammation. It is recommended to
119	adjust ferritin for inflammation with CRP and alpha(1)-acid glycoprotein using the BRINDA
120	method in this population <sup>40,41</sup> . However, NHANES did not measure alpha(1)-acid glycoprotein
121	in the cycles we included. In addition, a linear relationship was not observed between log-
122	transformed ferritin and log-transformed CRP, suggesting that the BRINDA method was not
123	appropriate for this data <sup>42</sup> . Therefore, we did not adjust ferritin for inflammation, similar to the
124	approach taken by previous studies 9. IDA was defined as anemia and ID using each iron
125	indicator separately (ferritin, TfR, and total body iron) <sup>43</sup> .

### **Body mass index**

We calculated pre-pregnancy BMI (kg/m<sup>2</sup>) based on pre-pregnancy weight (self-reported) and height (measured to the nearest mm in the Mobile Examination Center). We used the following BMI categories developed by the World Health Organization: underweight (< 18.5 kg/m<sup>2</sup>), normal (18.5-24.9 kg/m<sup>2</sup>), overweight (25-29.9 kg/m<sup>2</sup>), and obese ( $\geq$ 30 kg/m<sup>2</sup>)<sup>44</sup>.

### 131 Covariates

Maternal and household characteristics were collected via demographic and reproductive
 questionnaires. Based on prior literature <sup>7,9,11,45</sup>, we identified maternal age, race/ethnicity,
 maternal education, family income (NHANES calculated as poverty:income ratio) <sup>46</sup>, and

pregnancy trimester as confounders for inclusion as covariates in our models. Parity was 135 considered but was not included due to high amounts of missing data (approximately 30%). 136 Maternal age and self-reported race/ethnicity variables did not have missing data. The 137 maternal age variable was used as continuous in the analyses. The race/ethnicity variable was 138 used as a categorical variable based on the NHANES created levels, Mexican American, Other 139 140 Hispanic, non-Hispanic White, non-Hispanic Black, and Other Race – Including Multi-Racial. The 'Other' race category included participants selecting from various Asian, Pacific Islander, 141 and Native American categories, as well as those selecting multiple races. NHANES cycles from 142 143 1999-2006 oversampled Mexican-American ethnicity, and therefore estimates for Hispanic ethnicity from those cycles represent primarily Mexican-American ethnicity 144 (https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/99-10-analytic-guidelines.pdf). Due 145 to small sample size in our current study, we combined the Mexican-American and Other 146 Hispanic categories into one Hispanic category. However, it should be noted that the Hispanic 147 category reliably represents only Mexican-American ethnicity from 1999-2006 (48). 148 There was one participant missing maternal education data, and this observation was 149 collapsed with the high school diploma or less category, resulting in the final category of 'high 150 school diploma or less/unknown.' Final maternal education categories were: high school diploma 151 or less/unknown, some college, and college graduate. There were eighty-nine participants with 152 missing family income data. These participants were coded as a separate unknown category. The 153 154 final income categories were: poverty:income ratio < 130%, poverty:income ratio  $\ge 130$ , and unknown. Gestational age was self-reported as months in NHANES, and we used this 155 156 information to categorize participants as first trimester (0-3 months), second trimester (4-6 157 months), and third trimester (7-9 months). Participants who did not know their gestational age or

did not know they were pregnant were coded as unknown (n = 178). There were five participants
missing gestational age data, and these observations were collapsed with participants who
reported an unknown gestational age. Final trimester categories were: first trimester, second
trimester, third trimester, and unknown.

### 162 **Statistical analysis**

All data were analyzed using weighted statistics in SAS version 9.4 (Cary, NC) and Stata

version 18 (College Station, TX), as recommended by the NHANES website

165 (<u>https://www.cdc.gov/nchs/nhanes/index.htm</u>). Data merging, cleaning, and descriptive statistics

were performed in SAS, while adjusted models were performed in Stata. Survey methods were

used in both SAS and Stata to account for the complex sampling design of the NHANES survey,

including strata, cluster, and mobile examination center weights.

169 Descriptive statistics, including percentages and standard errors, were conducted in the total

sample and by the outcomes of interest, ID, anemia, and IDA, using weighted Chi-square tests.

171 For our primary analysis, ferritin, TfR, total body iron, and Hb were assessed by BMI category

and by continuous BMI. The iron biomarkers ferritin and TfR did not follow a normal

distribution, and thus were log transformed for analyses. Total body iron and Hb followed a

174 normal distribution and were not transformed. Associations between iron biomarker

175 concentrations and BMI (both continuous and categorical) were tested using weighted multiple

176 linear regression models adjusted for age, race/ethnicity, education level, family income, and

trimester of pregnancy. When analyzing BMI as a categorical variable, the Bonferroni

adjustment for multiple comparisons was used when performing pairwise comparisons.

179 Prevalence ratios and prevalence differences of ID, anemia, and IDA with their respective

180 confidence intervals were calculated by BMI category using Poisson regression models with181 robust error variance.

All Poisson regression models calculating prevalence were performed with and without covariates. Covariates included in all models were: age, race/ethnicity, education level, family income, and trimester of pregnancy. If the number of cases was < 30 for any model, then the estimates for those analyses were deemed unreliable and have been noted in the results <sup>47</sup>. Statistical significance was defined as p < 0.05 for all models.

## **187 Results**

# **188 Overall Population Characteristics**

189 The mean (standard error) age for the pregnant women in this study was 28.0 (0.29) years.

190 Sample characteristics are reported in the total sample and by ID (based on total body iron),

anemia (based on Hb), and IDA (based on total body iron and Hb) in Table 1. Approximately

192 30% of women graduated from college and 24% had a family income below 130% of the poverty

to income ratio. Overall, approximately half of the sample size had a normal pre-pregnancy BMI

and were of non-Hispanic White race/ethnicity. The prevalence of ID (based on total body iron),

anemia, and IDA (based on total body iron and Hb) were 14%, 8%, and 3%, respectively, and the

196 prevalence of inflammation was 48% (S1 Table). The prevalence of ID, anemia, and IDA were

197 similar across most characteristics but were all highest during the third trimester and among non-

198 Hispanic Black women.

Variables	<b>Total Sample</b> N=1156		Iron Deficiency <sup>a</sup> N=211		Anemia <sup>b</sup> N=100		IDA <sup>c</sup> N=49	
	$\mathbf{N}^{\mathbf{d}}$	% (SE) <sup>e</sup>	Ν	% (SE)	Ν	% (SE)	Ν	% (SE)
			(cases)		(cases)		(cases)	
Age groups								
18-24	428	31.7 (1.88)	100	17.6 (3.14)	36	7.65 (2.16)	21	4.12 (1.59)
25-29	352	28.7 (1.81)	66	16.4 (3.16)	34	7.36 (1.90)	16	2.47 (0.88)
30-34	258	23.2 (2.02)	34	14.3 (3.75)	19	7.40 (2.45)	7	2.14 (1.10)
35-49	118	16.4 (2.41)	11	3.44 (1.31)	11	7.88 (3.36)	5	1.43 (0.71)
Overall p-value				0.03		1.00		0.31
Race/Ethnicity								
Hispanic	401	22.3 (2.00)	89	17.5 (2.56)	38	8.35 (2.05)	21	3.07 (0.91)
NH White	512	53.2 (3.03)	72	10.6 (1.99)	25	3.28 (1.29)	14	1.66 (0.93)
NH Black	170	14.5 (1.89)	39	23.3 (4.30)	30	18.5 (3.81)	12	7.67 (2.85)
NH Other	73	9.97 (1.96)	11	12.7 (6.94)	7	12.7 (6.01)	2	0.64 (0.47)
Overall p-value				0.09		< 0.001		0.01
Education								
HS diploma or less/unknown	597	41.3 (2.45)	123	16.3 (2.09)	58	8.70 (1.77)	29	2.87 (0.74)
Some college	305	28.9 (2.37)	70	21.3 (3.95)	29	8.43 (2.35)	17	4.99 (2.00)
College graduate	254	29.9 (2.54)	18	4.33 (2.44)	13	5.11 (2.11)	3	0.41 (0.24)
Overall p-value				0.007		0.41		0.004
Family income (poverty:incom	ne ratio)							
< 130%	365	24.2 (1.90)	73	15.1 (2.35)	40	10.2 (1.92)	18	3.91 (1.17)
≥130%	702	68.0 (2.10)	116	13.5 (1.70)	52	6.68 (1.54)	27	2.44 (0.83)
Unknown/missing	89	7.80 (1.19)	22	16.5 (4.63)	8	7.07 (3.65)	4	1.83 (1.14)
Overall p-value				0.72		0.33		0.35
Pregnancy trimester								

Table 1: Characteristics of pregnant women (18-49 years of age) from NHANES 1999-2010 for the total sample, by iron
 deficiency, anemia, and iron deficiency anemia.

First (0-3)	178	19.2 (1.88)	9	2.65 (1.23)	5	2.09 (1.18)	2	0.98 (0.87)
Second (4-6)	406	30.1 (2.20)	55	11.2 (2.21)	31	6.86 (1.84)	16	2.36 (0.84)
Third (7-10)	389	30.9 (2.21)	111	23.7 (3.24)	48	11.7 (2.83)	25	4.07 (1.63)
Unknown/missing	183	19.9 (1.94)	36	15.0 (4.33)	16	7.40 (2.21)	6	2.98 (1.50)
Overall p-value				< 0.001		0.02		0.38
Pre-pregnancy BMI (kg/m <sup>2</sup> )								
Underweight, <18.5	66	5.35 (1.05)	17	12.1 (4.56)	7	5.14 (2.48)	6	4.41 (2.33)
Normal, 18.5-24.9	609	52.4 (2.15)	113	13.8 (2.10)	53	7.05 (1.70)	30	3.20 (1.04)
Overweight, 25.0-29.9	265	21.7 (1.74)	49	18.5 (3.12)	23	8.81 (2.48)	9	2.63 (1.25)
Obese ≥30.0	216	20.5 (1.87)	32	10.7 (3.02)	17	8.11 (2.71)	4	1.28 (0.85)
Overall p-value				0.31		0.82		0.48

<sup>a</sup> Iron deficiency was defined based on total body iron < 0 mg/kg. Total body iron was calculated using ferritin and transferrin receptor</li>
 using Cook's equation <sup>30</sup>.

203 <sup>b</sup> Anemia was defined based on hemoglobin < 11 g/dL.

<sup>c</sup> IDA was defined as both total body iron < 0 mg/kg and hemoglobin < 11 g/dL.

<sup>d</sup>N values were non-weighted.

<sup>e</sup> Percentages and standard errors for all columns were weighted and analyzed using chi-square tests.

207 Abbreviations: BMI=Body mass index; HS=High school; IDA=Iron deficiency anemia; NH=Non-Hispanic; SE=Standard error.

### **Iron Status by BMI Category** 208

Ferritin and total body iron concentrations were slightly lower in women with pre-pregnancy 209 BMI in the normal and overweight categories compared to the underweight and obese categories, 210 but these differences have very low confidence (p>0.10; Fig 1). There were also no statistical or 211 meaningful differences between BMI groups in TfR or Hb. We tested if continuous pre-212 pregnancy BMI (kg/m<sup>2</sup>) was associated with concentrations of iron biomarkers (ferritin, TfR, 213 total body iron, and Hb), and we found no association in unadjusted or adjusted models (p>0.10; 214 results not shown). 215 216 Fig 1. Iron status biomarker concentrations by BMI category (n=1156). Serum 217

concentrations of: A) Ferritin (p = 0.11), B) TfR (p = 0.70), C) Total Body Iron (p = 0.13), and 218 D) Hb (p = 0.74) stratified by BMI categories (Underweight, < 18.5 kg/m<sup>2</sup>; Normal, 18.5-24.9 219 kg/m<sup>2</sup>: Overweight, 25-29.9 kg/m<sup>2</sup>: Obesity, > 30 kg/m<sup>2</sup>). Data are presented as adjusted least 220 221 squares means  $\pm$  95% confidence intervals (1.96\*standard errors of the means). Differences between groups were assessed using weighted multiple linear regression models adjusted for age. 222 race/ethnicity, education level, family income (PIR), and trimester of pregnancy and adjusted for 223 multiple comparisons using the Bonferroni method. Ferritin and transferrin receptor (TfR) were 224 log-transformed in the models to account for non-normal distributions. Means and confidence 225 226 intervals were exponentiated for presentation. Total body iron was calculated using Ferritin and transferrin receptor using Cook's equation <sup>30</sup>. Abbreviations: BMI=Body mass index (kg/m<sup>2</sup>); 227 Ferritin=Ferritin; Hb=Hemoglobin; PIR=Poverty:income ratio; TfR=Transferrin receptor. 228

229

- Similarly, we found no differences in the prevalence of ID (total body iron < 0 mg/kg),
- anemia (Hb < 11 g/dL), or IDA by pre-pregnancy BMI (Table 2). However, because the number
- of IDA cases was low within each BMI category, the estimates in adjusted models should be
- 233 considered unreliable and interpreted with caution. The number of cases for all outcomes was
- also low in the underweight (BMI  $< 18.5 \text{ kg/m}^2$ ) category.

Table 2: Weighted prevalences and prevalence ratios and differences of iron deficiency and anemia status in pregnant women ages 18-49 by pre-pregnancy BMI from NHANES 1999-2010 (n = 1156).

Pre-pregnancy BMI categories by iron status:	Prevalence [% (Standard Error)]	Cases (N) <sup>a</sup>	Unadjusted Prevalence Ratio (95% CI) <sup>b</sup>	Adjusted Prevalence Ratio (95% CI) <sup>c</sup>	Adjusted Prevalence Difference [excess cases per 100 (95% CI)]			
ID (Ferritin < 12 ug/L)					· · · · ·			
Underweight BMI, < 18.5	15.5 (5.31)	18	0.75 (0.37, 1.52) <sup>d</sup>	0.78 (0.39, 1.57) <sup>d</sup>	-4.51 (-16.3, 7.25) <sup>d</sup>			
Normal BMI, 18.5-24.9	20.6 (2.78)	156	Reference	Reference	Reference			
Overweight BMI, 25-29.9	21.2 (4.18)	64	1.03 (0.64, 1.64)	0.98 (0.64, 1.51)	-0.43 (-9.32, 8.46)			
Obese BMI, $\geq 30$	15.5 (4.06)	38	0.75 (0.41, 1.38)	0.72 (0.41, 1.27)	-5.79 (-15.1, 3.53)			
ID (TfR > 4.4 mg/L)								
Underweight BMI, < 18.5	12.5 (4.35)	16	0.72 (0.34, 1.49) <sup>d</sup>	0.97 (0.49, 1.93) <sup>d</sup>	-0.53 (-11.6, 10.6) <sup>d</sup>			
Normal BMI, 18.5-24.9	17.4 (2.54)	110	Reference	Reference	Reference			
Overweight BMI, 25-29.9	17.5 (2.91)	46	1.01 (0.63, 1.62)	1.09 (0.72, 1.64)	1.42 (-5.77, 8.62)			
Obese BMI, $\geq 30$	14.7 (3.26)	40	0.85 (0.52, 1.39)	0.93 (0.61, 1.41)	-1.24 (-7.90, 5.42)			
ID (Total body iron < 0 mg/l	(xg) <sup>e</sup>							
Underweight BMI, < 18.5	12.7 (4.56)	17	0.91 (0.43, 1.92) <sup>d</sup>	0.88 (0.41, 1.89) <sup>d</sup>	-1.74 (-11.4, 7.94) <sup>d</sup>			
Normal BMI, 18.5-24.9	13.9 (2.10)	113	Reference	Reference	Reference			
Overweight BMI, 25-29.9	18.5 (3.12)	49	1.33 (0.86, 2.05)	1.27 (0.89, 1.82)	3.88 (-1.95, 9.70)			
Obese BMI, $\geq 30$	10.7 (3.02)	32	0.77 (0.40, 1.49)	0.75 (0.39, 1.45)	-3.49 (-11.0, 4.06)			
Anemia (Hb < 11 g/dL) <sup>f</sup>								
Underweight BMI, < 18.5	5.14 (2.48)	7	0.73 (0.25, 2.13) <sup>d</sup>	0.88 (0.28, 2.77) <sup>d</sup>	-0.90 (-8.57, 6.77) <sup>d</sup>			
Normal BMI, 18.5-24.9	7.05 (1.70)	53	Reference	Reference	Reference			
Overweight BMI, 25-29.9	8.81 (2.48)	23	1.25 (0.61, 2.55)	1.08 (0.53, 2.19)	0.58 (-4.98, 6.14)			
Obese BMI, $\geq 30$	8.11 (2.71)	17	1.15 (0.55, 2.43)	0.99 (0.49, 2.01)	-0.05 (-5.29, 5.19)			
ID Anemia (Hb < 11 g/dL and Total body iron < 0 mg/kg) <sup>f</sup>								
Underweight BMI, < 18.5	4.41 (2.33)	6	1.38 (0.40, 4.71) <sup>d</sup>	1.38 (0.39, 4.90) <sup>d</sup>	1.44 (-4.84, 7.72) <sup>d</sup>			
Normal BMI, 18.5-24.9	3.20 (1.04)	30	Reference	Reference	Reference			
Overweight BMI, 25-29.9	2.63 (1.25)	9	0.82 (0.29, 2.35)	0.62 (0.24, 1.57)	-1.44 (-4.01, 1.14)			
Obese BMI, $\geq 30$	1.28 (0.85)	4	0.40 (0.09, 1.70)	0.27 (0.08, 0.89)	-2.75 (-5.05, -0.44)			

<sup>a</sup> N values represent non-weighted number of cases; all other analyses were weighted.

<sup>b</sup> Prevalence ratios and differences were calculated using Poisson regression models with robust error variance.

- <sup>c</sup> The covariates included in all adjusted models were age, race/ethnicity, education level, family income, and trimester of pregnancy.
- <sup>d</sup> Estimates for the underweight BMI ( $< 18 \text{ kg/m}^2$ ) group may be unreliable because the number of cases was < 30 for all models <sup>47</sup>.
- <sup>e</sup> Total body iron was calculated using ferritin and transferrin receptor using Cook's equation <sup>30</sup>.
- <sup>f</sup>Estimates may be unreliable due to sample size of cases < 30 for some BMI categories <sup>47</sup>.
- Abbreviations: BMI=Body mass index; CI=Confidence interval; Ferritin=Ferritin; ID=Iron deficiency; IDA=Iron deficiency anemia;
- 244 Hb=Hemoglobin; TfR=Transferrin receptor

245

# 246 **Discussion**

Based on NHANES data from 1999-2010, pre-pregnancy overweight and obesity were not
associated with increased prevalence of ID or anemia during pregnancy in this US population.

Although pre-pregnancy obesity is strongly linked to increased risk of adverse pregnancy

250 outcomes, based on our results, it was not associated with ID or anemia.

To our knowledge, the association between iron status and BMI has not been examined with 251 nationally representative data in US pregnant women using biomarkers of either the circulating 252 iron or storage iron components. The circulating iron component is measured with biomarkers 253 254 such as TfR, serum iron, or transferrin saturation. Two prior cross-sectional cohort studies conducted in the US observed no association between circulating iron biomarkers and BMI 255 groups <sup>17,18</sup>, which is similar to our findings. Of note, one of these studies <sup>18</sup> was conducted in 256 257 adolescents (13-18 years of age) and the other <sup>17</sup> was limited by a small sample size (n=15 per group). Interestingly, studies from outside of the US have found contradictory results with some 258 finding no association between TfR and obesity <sup>19,22,48</sup> and others observing that TfR 259 concentrations were higher (indicating poorer iron status) in women with obesity <sup>19–21,49</sup>. 260 Our results for the storage iron component, measured by ferritin, are largely consistent with 261 other studies <sup>20,21,49</sup>. However, one study <sup>18</sup> found that higher concentrations of ferritin at mid-262 gestation and delivery were associated with classes two and three of obesity (BMI 35-39.9 and  $\geq$ 263 40 kg/m<sup>2</sup>) compared with normal pre-pregnancy BMI. In the current study, we did not have a 264 265 large enough sample size to stratify by obesity class. In addition, although NHANES recorded trimester at the time of assessment for each pregnant participant, there was not a large enough 266

sample size to test for interactions between BMI category and trimester in the current study.

In addition to its function as an iron storage biomarker, ferritin is an acute phase protein, 268 susceptible to inflammation, measured by CRP in the NHANES study. The prevalence of 269 inflammation based on CRP >5 mg/L in our sample was 48%, which is similar to results reported 270 271 by Mei et al.<sup>9</sup>. Previous studies have observed higher concentrations of inflammatory markers such as CRP, interleukin-6, leptin, and hepcidin in women with obesity compared with normal 272 weight <sup>18,20</sup>. In our study, pregnant women with obesity had significantly higher concentrations 273 of the inflammatory protein, CRP, (mean (standard error) = 13.2 (1.5) mg/L) than other BMI 274 categories (mean (standard error) = 6.6 (0.6) mg/L; p < 0.001), suggesting that elevated serum 275 276 CRP is more strongly related to obesity in this sample than with acute inflammatory response. Others have found that chronic inflammation may be connected to lower ferritin concentrations 277 through the regulatory hormone hepcidin. Hepcidin increases when iron concentrations in 278 circulation are adequate or in the presence of inflammation <sup>50</sup> and acts by blocking iron release 279 from storage into circulation via degradation of the efflux protein, ferroportin <sup>51</sup>. This would 280 suggest that obesity-related inflammation would lead to lower circulating ferritin concentrations. 281 which was not supported by our findings. However, our results may be explained by the fact that 282 hepcidin rises only moderately in individuals with obesity when compared to those with serious 283 inflammatory diseases <sup>50</sup>. Testing this mechanism was outside the scope of our study, since 284 NHANES has not measured hepcidin in laboratory measures. Last, the functional iron 285 compartment, measured with Hb, was not associated with BMI categories in our sample, which 286 is consistent with prior studies <sup>18,19,21,22</sup>. 287

Overall, we did not find any meaningful association with iron status biomarkers and BMI when adjusting for age, race/ethnicity, education level, family income, and trimester of pregnancy. Although our results differed from other studies, there could be a variety of factors

explaining these differences. First, distinct populations may have different associations between 291 BMI and ID, and studies conducted in other countries may be measuring completely different 292 populations. Second, there may be other unmeasured confounding factors such as access to 293 medical care and food security status. For instance, access to medical care during pregnancy may 294 delay diagnosis of ID and anemia and in turn, prescription of iron supplements during critical 295 296 stages of pregnancy when it is needed most, and that pregnant women with food insecurity are more likely to have both lower iron intake and iron deficiency <sup>52</sup>. Last, prenatal iron 297 supplementation could also be a contributing factor to iron status. Analyses of NHANES data 298 from 1996 to 2006 <sup>53</sup> show that 77% of pregnant women self-reported taking a supplement 299 containing iron (48 mg) in the previous 30 days, but previous studies have also found lower 300 supplement use and iron intake in non-Hispanic Black pregnant women <sup>54,55</sup>. Our work focused 301 302 on iron status (concentrations and prevalences) rather than dietary sources such as iron supplementation, but based on prior evidence, we may infer that the majority of pregnant women 303 in our analysis took an iron supplement during pregnancy. 304 The prevalence of ID in this study, based on total body iron, was 14%, which was similar to 305 ID prevalence (also based on total body iron) observed in the Gupta et al., (16%)<sup>7</sup>, and Mei et 306 al., (18%)<sup>9</sup>, both previous NHANES studies. The prevalence of anemia in our study was 8%, 307 which was similar to the prevalence of 5% found by Mei et al.<sup>9</sup>. Our estimate of IDA was also 308 similar to the 3% reported by Gupta et al.<sup>7</sup>. Slight discrepancies in prevalence rates between 309 310 these studies may be explained by differing NHANES cycles included in analysis and differing age ranges. In the study by Gupta et al., the same cycles were used, but the age range (12-49 yrs.) 311

312 was wider. The study by Mei et al. used fewer NHANES cycles (1999-2006) and included

313 women aged 15-39 yrs. Overall, NHANES studies, including our current study, have observed

that prevalence of ID is higher than prevalence of anemia and IDA. Total anemia prevalence (58%) in pregnant women is low in the US, compared with the global prevalence of 37% <sup>56</sup>.

## 316 Strengths & Limitations

This study's main strength is that it uses a nationally representative sample of US 317 318 pregnant women. Further, NHANES oversampled pregnant women during the 1999-2006 cycles 319 and used comprehensive methods to assess iron status including the total body iron indicator. 320 Our study has, however, some limitations. First, the cross-sectional design precludes establishing 321 a temporal relationship. Second, as in any observational study, residual confounding may be present despite our effort to adjust our models, particularly due to not being able to include 322 parity. Third, pre-pregnancy weight was self-reported, which may misclassify maternal BMI. 323 Fourth, due to the cross-sectional nature of the survey, we were unable to calculate gestational 324 weight gain, which would have been more accurate in testing its association with iron status. 325 Another potential confounder is gestational diabetes, which is only collected in two out of the six 326 cycles included in this analysis, thus, we were unable to account for this factor. Fifth, the most 327 recent iron status biomarker data combined with full pregnancy data (trimester or gestational 328 329 age) in NHANES is over ten years old, and there is some evidence that it may overestimate the prevalence of anemia in low-income women <sup>57</sup>. Therefore, it is unknown whether these data are 330 representative of the current population. NHANES should consider future collection of both iron 331 332 status biomarkers and all variables needed to assess iron status during pregnancy. Last, the number of cases of anemia and especially of IDA was small in the overall sample and even 333 smaller when stratified by BMI groups, making adjusted prevalence estimates less reliable and 334 requiring caution for interpretation. 335

### 336 Conclusions

Overweight and obesity are common, and the prevalence continues to rise in pregnant 337 women in the US. However, using the NHANES 1999-2010 cycles, we did not find women with 338 pre-pregnancy overweight or obesity to have an increased likelihood for ID or anemia during 339 pregnancy when compared to pre-pregnancy normal weight. Previous studies reporting an 340 association between BMI and iron status were conducted in different populations and may have 341 342 been confounded by other demographic factors. Given these results and the fact that prenatal iron deficiency remains a significant public health concern, there is a need to continue collection of 343 high-quality national data on these biomarkers during pregnancy to assess progress over time in 344 alleviating maternal health disparities. 345

346

# 347 Acknowledgements

348 The authors would like to acknowledge the contribution of Elizabeth Soucy, who assisted

349 with the initial literature search for this project.

### 350

# 351 **References**

- Sundararajan S, Rabe H. Prevention of iron deficiency anemia in infants and toddlers. Pediatric
   Research. 2021;89(1):63–73. PMID: 32330927
- Scholl TO. Maternal iron status: Relation to fetal growth, length of gestation, and iron endowment
   of the neonate. Nutrition Reviews. 2011;69(SUPPL. 1):23–29. PMID: 22043878
- Marchi J, Berg M, Dencker A, Olander EK, Begley C. Risks associated with obesity in pregnancy, for
   the mother and baby: A systematic review of reviews. Obesity Reviews. 2015;16(8):621–638.
   PMID: 26016557
- Rasmussen KM. Association of maternal obesity before conception with poor lactation
   performance. Annual review of nutrition. 2007;27:103–121. PMID: 17341160
- Pfeiffer CM, Sternberg MR, Caldwell KL, Pan Y. Race-Ethnicity Is Related to Biomarkers of Iron and Iodine Status after Adjusting for Sociodemographic and Lifestyle Variables in NHANES 2003–2006.
   The Journal of Nutrition. 2013 Jun 1;143(6):977S-985S.

- Briscoll AK, Gregory ECW. Increases in Prepregnancy Obesity: United States, 2016-2019. NCHS data
   brief. 2020;(392):1–8. PMID: 33270551
- Gupta PM, Hamner HC, Suchdev PS, Flores-Ayala R, Mei Z. Iron status of toddlers, nonpregnant females, and pregnant females in the United States. American Journal of Clinical Nutrition.
   2017;106(Id):1640S-1646S. PMID: 29070559
- Miller EM. Iron status and reproduction in US women: National health and nutrition examination survey, 1999-2006. PLoS ONE. 2014;9(11):1999–2006. PMID: 25375360
- Mei Z, Cogswell ME, Looker AC, Pfeiffer CM, Cusick SE, Lacher DA, Grummer-Strawn LM.
   Assessment of iron status in US pregnant women from the national health and nutrition
   examination survey (NHANES), 1999-2006. American Journal of Clinical Nutrition.
   2011;93(6):1312–1320. PMID: 21430118
- Milman N. Iron and pregnancy--a delicate balance. Ann Hematol. 2006 Sep;85(9):559–565. PMID:
   16691399
- Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the
   United States. Journal of the American Medical Association. 1997;277(12):973–976. PMID:
   9091669
- Brannon PM, Taylor CL. Iron supplementation during pregnancy and infancy: Uncertainties and
   implications for research and policy. Nutrients. 2017;9(12):1–17. PMID: 29210994
- Pobee RA, Setorglo J, Klevor M, Murray-Kolb LE. The prevalence of anemia and iron deficiency
   among pregnant Ghanaian women, a longitudinal study. PLoS ONE. 2021;16(3 March):1–14. PMID:
   33760869
- Rockfield S, Chhabra R, Robertson M, Rehman N, Bisht R, Nanjundan M. Links between iron and
   lipids: Implications in some major human diseases. Pharmaceuticals. 2018;11(4):1–14.
- Cepeda-Lopez AC, Osendarp SJM, Melse-Boonstra A, Aeberli I, Gonzalez-Salazar F, Feskens E,
   Villalpando S, Zimmermann MB. Sharply higher rates of iron deficiency in obese Mexican women
   and children are predicted by obesity-related inflammation rather than by differences in dietary
   iron intake. American Journal of Clinical Nutrition. 2011;93(5):975–983.
- Wawer AA, Hodyl NA, Fairweather-Tait S, Froessler B. Are pregnant women who are living with
   overweight or obesity at greater risk of developing iron deficiency/anaemia? Nutrients.
   2021;13(5). PMID: 34067098
- 17. Dao MC, Sen S, Iyer C, Klebenov D, Meydani SN. Obesity during Pregnancy and Fetal Iron Status: is
   Hepcidin the link? J Perinatol. 2013;33(3):177–181.
- Cao C, Pressman EK, Cooper EM, Guillet R, Westerman M, O'Brien KO. Prepregnancy Body Mass
   Index and Gestational Weight Gain Have No Negative Impact on Maternal or Neonatal Iron Status.
   Reproductive Sciences. 2016;23(5):613–622. PMID: 26423600

 Garcia-Valdes L, Campoy C, Hayes H, Florido J, Rusanova I, Miranda MT, McArdle HJ. The impact of maternal obesity on iron status, placental transferrin receptor expression and hepcidin expression in human pregnancy. International Journal of Obesity. Nature Publishing Group; 2015;39(4):571– 578. PMID: 25614087

- Flynn AC, Begum S, White SL, Dalrymple K, Gill C, Alwan NA, Kiely M, Latunde-Dada G, Bell R, Briley
  AL, Nelson SM, Oteng-Ntim E, Sandall J, Sanders TA, Whitworth M, Murray DM, Kenny LC, Poston
  L. Relationships between maternal obesity and maternal and neonatal iron status. Nutrients.
  2018;10(8):1–10. PMID: 30061547
- 407 21. Jones AD, Zhao G, Jiang YP, Zhou M, Xu G, Kaciroti N, Zhang Z, Lozoff B. Maternal obesity during
  408 pregnancy is negatively associated with maternal and neonatal iron status. Eur J Clin Nutr. 2016
  409 Jan 27; PMID: 26813939
- Flores-Quijano ME, Vega-Sánchez R, Tolentino-Dolores MC, López-Alarcón MG, Flores-Urrutia MC,
   López-Olvera AD, Talavera JO. Is associated with changes in iron nutrition status and its
   homeostatic regulation in pregnancy. Nutrients. 2019;11(3):1–17. PMID: 30909605
- A13 23. NHANES NCHS Research Ethics Review Board Approval [Internet]. National Center for Health
  Statistics. 2019 [cited 2020 Dec 8]. Available from: https://www.cdc.gov/nchs/nhanes/irba98.htm
- 415 24. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2005-2006) [Internet]. National
  416 Center for Health Statistics. 2008 [cited 2020 Dec 8]. Available from:
  417 https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/labmethods/fertin d met roche.pdf
- 418 25. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2007-2008) [Internet]. National
  419 Center for Health Statistics. 2009. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2007420 2008/labmethods/fertin\_e\_met\_ferritin.pdf
- 421 26. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2005-2006)
   422 [Internet]. National Center for Health Statistics. 2008. Available from:
- 423 https://www.cdc.gov/NCHS/data/nhanes/nhanes\_05\_06/tfr\_d\_met\_transferrin\_receptor.pdf
- 424 27. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2007-2008)
  425 [Internet]. National Center for Health Statistics. 2009. Available from:
- 426 https://wwwn.cdc.gov/nchs/data/nhanes/2007-
- 427 2008/labmethods/tfr\_e\_met\_transferrin\_receptor.pdf
- 428 28. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2009-2010) [Internet]. National
  429 Center for Health Statistics. 2012. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2009430 2010/labmethods/fertin\_f\_met\_ferritin.pdf
- 431 29. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2009-2010)
  432 [Internet]. National Center for Health Statistics. 2012. Available from:
- 433 https://wwwn.cdc.gov/nchs/data/nhanes/2009-
- 434 2010/labmethods/tfr f met transferrin receptor.pdf
- 435 30. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003 May
  436 1;101(9):3359–3363. PMID: 12521995

Centers for Disease Control and Prevention. Recommendations to Prevent and Control Iron

437

31.

438 Deficiency in the United States [Internet]. 1998 Apr p. 1–36. Report No.: 47 (RR–3). Available from: 439 https://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm 440 32. Kolbe-Busch S, Lotz J, Hafner G, Blanckaert NJC, Claeys G, Togni G, Carlsen J, Röddiger R, Thomas L. 441 Multicenter evaluation of a fully mechanized soluble transferrin receptor assay on the Hitachi and 442 cobas integra analyzers. the determination of reference ranges. Clin Chem Lab Med. 2002 443 May;40(5):529-536. PMID: 12113300 444 CDC 1999-2000. Laboratory Procedure Manual. CBC with five-part differential NHANES 1999-2000 33. 445 [Internet]. [cited 2023 Oct 24]. Available from: 446 https://www.cdc.gov/nchs/data/nhanes/nhanes\_99\_00/lab25\_met\_complete\_blood\_count.pdf 447 34. CDC 2007-2008. Laboratory Procedure Manual. CBC with five-part differential NHANES 2007-2008. 35. 448 ACOG Practice Bulletin. Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. Obstet 449 Gynecol. 2021 Aug 1;138(2):e55-e64. PMID: 34293770 450 36. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2005-2006) [Internet]. 451 National Center for Health Statistics. 2007. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/labmethods/crp d met protein.pdf 452 453 37. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2007-2008) [Internet]. 454 National Center for Health Statistics. 2007. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/crp e met.pdf 455 456 38. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2009-2010) [Internet]. 457 National Center for Health Statistics. 2011. Available from: 458 https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/crp\_f\_met.pdf 459 Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, Blaabjerg O, Blirup-Jensen S, 39. 460 Carlström A, Petersen PH, Johnson AM, Milford-Ward A, Ritchie RF, Svendsen PJ, Whicher J. 461 Consensus of a group of professional societies and diagnostic companies on guidelines for interim 462 reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP 463 Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau 464 of Reference of the Commission of the European Communities. College of American Pathologists. 465 Eur J Clin Chem Clin Biochem. 1996 Jun;34(6):517–520. PMID: 8831057 466 40. Namaste SM, Rohner F, Huang J, Bhushan NL, Flores-Ayala R, Kupka R, Mei Z, Rawat R, Williams 467 AM, Raiten DJ, Northrop-Clewes CA, Suchdev PS. Adjusting ferritin concentrations for 468 inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia 469 (BRINDA) project. Am J Clin Nutr. 2017 Jul;106(Suppl 1):359S-371S. PMCID: PMC5490647 470 41. Namaste SML, Ou J, Williams AM, Young MF, Yu EX, Suchdev PS. Adjusting iron and vitamin A 471 status in settings of inflammation: a sensitivity analysis of the Biomarkers Reflecting Inflammation 472 and Nutritional Determinants of Anemia (BRINDA) approach. The American Journal of Clinical 473 Nutrition. 2020 Aug 1;112(Supplement 1):458S-467S.

474 42. Luo H, Geng J, Zeiler M, Nieckula E, Sandalinas F, Williams A, Young MF, Suchdev PS. A Practical
475 Guide to Adjust Micronutrient Biomarkers for Inflammation Using the BRINDA Method. J Nutr.
476 2023 Apr;153(4):1265–1272. PMCID: PMC10202121

- 43. Acharya S, Beard JL, Davidson FR, Davidsson L, Hertrampf ED, Jacobs M, Lynch SR, Stoltzfus RJ.
  478 Why iron is important and what do do about it: a new perspective. Washington (DC), INACG
  479 Secretariat; 2002 p. 1–50.
- 48. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert
  481 Committee. World Health Organ Tech Rep Ser. 1995;854:1–452. PMID: 8594834

482 45. Mei Z, Addo OY, Jefferds ME, Sharma AJ, Flores-Ayala RC, Brittenham GM. Physiologically based
483 serum ferritin thresholds for iron deficiency in children and non-pregnant women: a US National
484 Health and Nutrition Examination Surveys (NHANES) serial cross-sectional study. The Lancet
485 Haematology. 2021 Aug;8(8):e572–e582.

- 486
   46. U.S. Department of Agriculture, Food and Nutrition Service. WIC eligibility requirements | USDA 487
   487 FNS [Internet]. 2020 [cited 2019 Aug 23]. Available from: https://www.fns.usda.gov/wic/wic 488 eligibility-requirements
- 47. Parker JD, Talih M, Malec DJ, Beresovsky V, Carroll M, Gonzalez JF, Hamilton BE, Ingram DD,
  490 Kochanek K, McCarty F, Moriarity C, Shimizu I, Strashny A, Ward BW. National Center for Health
  491 Statistics Data Presentation Standards for Proportions. Vital Health Stat 2. 2017 Aug;(175):1–22.
  492 PMID: 30248016

48. Vega-Sánchez R, Tolentino-Dolores MC, Cerezo-Rodríguez B, Chehaibar-Besil G, Flores-Quijano ME.
494 Erythropoiesis and Red Cell Indices Undergo Adjustments during Pregnancy in Response to
495 Maternal Body Size but not Inflammation. Nutrients. Multidisciplinary Digital Publishing Institute;
496 2020 Apr;12(4):975.

- 49. Flores-Quijano ME, Montalvo-Velarde I, Vital-Reyes VS, Rodríguez-Cruz M, Rendón-Macías ME,
  498 López-Alarcón M. Longitudinal Analysis of the Interaction Between Obesity and Pregnancy on Iron
  499 Homeostasis: Role of Hepcidin. Arch Med Res. 2016 Oct;47(7):550–556. PMID: 28262197
- 50. Tussing-Humphreys L, Pustacioglu C, Nemeth E, Braunschweig C. Rethinking Iron Regulation and
   501 Assessment in Iron Deficiency, Anemia of Chronic Disease, and Obesity: Introducing Hepcidin. J
   502 Acad Nutr Diet. 2012 Mar;112(3):391–400. PMCID: PMC3381289
- 503 51. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin
  504 Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science.
  505 2004 Dec 17;306(5704):2090–2093. PMID: 15514116
- 506 52. Park CY, Eicher-Miller HA. Iron deficiency is associated with food insecurity in pregnant females in
   507 the United States: National Health and Nutrition Examination Survey 1999-2010. Journal of the
   508 Academy of Nutrition and Dietetics. 2014 Dec 1;114(12):1967–1973.
- 53. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the
  United States. J Nutr. 2013 Apr;143(4):486–492. PMCID: PMC4745881

- 54. Cogswell ME, Kettel-Khan L, Ramakrishnan U. Iron Supplement Use among Women in the United
  States: Science, Policy and Practice. J Nutr. 2003 Jun 1;133(6):1974S-1977S.
- 513 55. Liu J, Zhu X, Fulda KG, Chen S, Tao MH. Comparison of Dietary Micronutrient Intakes by Body
  514 Weight Status among Mexican-American and Non-Hispanic Black Women Aged 19–39 Years: An
  515 Analysis of NHANES 2003–2014. Nutrients. Multidisciplinary Digital Publishing Institute; 2019
  516 Dec;11(12):2846.
- 517 56. WHO. Anaemia in women and children [Internet]. World Health Organization. 2021 [cited 2023
  518 Aug 12]. Available from:
- 519 https://www.who.int/data/gho/data/themes/topics/anaemia\_in\_women\_and\_children
- 57. Kanu FA, Hamner HC, Scanlon KS, Sharma AJ. Anemia Among Pregnant Women Participating in the
  Special Supplemental Nutrition Program for Women, Infants, and Children United States, 20082018. MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):813–819. PMID: 35737575
- 523

524

# 525 Supporting Information

- 526 S1 Table: Weighted medians and prevalences of inflammation, iron, and anemia
- biomarkers in pregnant women of reproductive age (18-49 years of age) from the NHANES
  (1999-2010) study (n=1156).
- 529 S2 Table: Weighted prevalences and prevalence ratios and differences of iron deficiency
- and anemia status in pregnant women ages 18-49 by race/ethnicity from NHANES 19992010 (n = 1156).
- 551 **2**010 (n 1150).
  - 532 S3 Table: Weighted prevalences and prevalence ratios and differences of iron deficiency
  - and anemia status in pregnant women ages 18-49, by race/ethnicity from NHANES 1999-
  - 534 2010 (n=1156) using Mexican American and Hispanic Other categories.

535




Figure 1